admin
Anthropic said its AI, Claude, had found a new enzyme system with gene‑editing potential. That sounded like a big win for the Silicon Valley narrative: a friendly robot in a lab, doing science by itself. But a Research Assistant at the University of Copenhagen, Mario Rodríguez Mestre, pushed back hard. He says he and his team have been studying those same enzymes for years and even shared unpublished work with Anthropic’s Claude. That claim changes this from a feel‑good AI story into a serious question about credit, data use, and corporate hype.
What Mestre Says — and why provenance matters
Mestre says his group first found the enzyme system in jumbo bacteriophages and nicknamed parts of it “jumbotrons.” They ran analyses, shared draft manuscripts and figures in private, and even appear on a related patent filing. Mestre says those findings were uploaded to Claude while his team used the tool for ordinary work. If Anthropic’s models used those private uploads, then Anthropic’s boast that Claude “took the first steps” looks shaky. Provenance isn’t just academic hair‑splitting — it decides who gets credit, who can patent, and who owns scientific ideas.
Anthropic’s claim and their defense
Anthropic’s scientists say hundreds of Claude agents scanned massive gene databases and flagged a repeat pattern tied to reverse transcriptases. They ran lab checks and wrote up a technical report. The company says it wasn’t trained on user transcripts and that it didn’t have prior knowledge of Mestre’s unpublished work. Fine words — but when a private AI lab claims a discovery that overlaps with a researcher’s unpublished files, a simple denial won’t be enough. We need timestamps, agent logs, and clear data policies, not marketing copy aimed at investors.
Why this matters for science, IP and investors
This is about more than one enzyme system. Big AI firms have millions of users — including scientists who upload sensitive data. If those uploads can end up informing company outputs or model retraining without clear consent, researchers lose control of their work. Investors should also care. Anthropic is preparing for a massive public offering, and big claims about autonomous discovery can inflate valuations. The right question is whether companies are racing to make press releases and IPO prospectuses before sorting out fair use and intellectual property.
Bottom line: demand transparency, or don’t call it a discovery
We should applaud scientific progress, but not when it’s wrapped in PR spin. If an upstart AI lab claims its chatbot independently discovered a gene‑editing system, independent verification is required — and that includes checking whether unpublished research fed the model. Regulators, journals, and investors need to insist on logs, timestamps, and clear data‑use rules. Otherwise the phrase “AI discovered” will mean “AI repeated what someone else told it,” with the company taking the applause. That’s not science. It’s theater — and taxpayers, scientists, and shareholders deserve better.
